Beta

Shattuck labs, inc.STTK.US Overview

US StockHealthcare
(No presentation for STTK)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

STTK AI Insights

STTK Overall Performance

STTK AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

STTK Recent Performance

1.20%

Shattuck labs, inc.

-1.64%

Avg of Sector

-0.21%

S&P500

STTK PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check STTK's Trend

STTK Key Information

STTK Valuation Metrics

STTK Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Price of STTK

STTK FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.02
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
585.00
PB Ratio
7.11
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-4880.90%
Revenue Growth (YoY)
-82.52%
Profit Growth (YoY)
-82.52%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.02
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
585.00
PB Ratio
7.11
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-4880.90%
Revenue Growth (YoY)
-82.52%
Profit Growth (YoY)
-82.52%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is STTK's latest earnings report released?

    The most recent financial report for Shattuck labs, inc. (STTK) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating STTK's short-term business performance and financial health. For the latest updates on STTK's earnings releases, visit this page regularly.

  • How much cash does STTK have?

    At the end of the period, Shattuck labs, inc. (STTK) held Total Cash and Cash Equivalents of 54.19M, accounting for 0.6 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is STTK's EPS continuing to grow?

    According to the past four quarterly reports, Shattuck labs, inc. (STTK)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of STTK?

    Shattuck labs, inc. (STTK)'s Free Cash Flow (FCF) for the period is -8.49M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 51.12% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of STTK?

    The latest valuation data shows Shattuck labs, inc. (STTK) has a Price-To-Earnings (PE) ratio of -7.48 and a Price/Earnings-To-Growth (PEG) ratio of 0.53. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.

STTK Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1